BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

897 related articles for article (PubMed ID: 17064683)

  • 1. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective effect of rutin, a polyphenolic flavonoid against haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Fundam Clin Pharmacol; 2007 Oct; 21(5):521-9. PubMed ID: 17868205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protective effect of adenosine reuptake inhibitors in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacology; 2007; 79(3):171-83. PubMed ID: 17377417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1130-8. PubMed ID: 17513028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theophylline, adenosine receptor antagonist prevents behavioral, biochemical and neurochemical changes associated with an animal model of tardive dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Rep; 2007; 59(2):181-91. PubMed ID: 17556796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Withania somnifera root extract on reserpine-induced orofacial dyskinesia and cognitive dysfunction.
    Naidu PS; Singh A; Kulkarni SK
    Phytother Res; 2006 Feb; 20(2):140-6. PubMed ID: 16444668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-phenyl-N-tert-butylnitrone prevents oxidative stress in a haloperidol-induced animal model of tardive dyskinesia: investigating the behavioural and biochemical changes.
    Daya RP; Tan ML; Sookram CD; Skoblenick K; Mishra RK
    Brain Res; 2011 Sep; 1412():28-36. PubMed ID: 21816389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean ginseng extract attenuates reserpine-induced orofacial dyskinesia and improves cognitive dysfunction in rats.
    Sanghavi CR; Barhate SA; Mahajan MS; Mohan M; Kasture SB
    Nat Prod Res; 2011 Apr; 25(7):704-15. PubMed ID: 20628966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ebselen attenuates haloperidol-induced orofacial dyskinesia and oxidative stress in rat brain.
    Burger ME; Fachinetto R; Zeni G; Rocha JB
    Pharmacol Biochem Behav; 2005 Jul; 81(3):608-15. PubMed ID: 15953628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential striatal levels of TNF-alpha, NFkappaB p65 subunit and dopamine with chronic typical and atypical neuroleptic treatment: role in orofacial dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Aug; 32(6):1473-8. PubMed ID: 18554768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurochemical changes associated with chronic administration of typical antipsychotics and its relationship with tardive dyskinesia.
    Bishnoi M; Chopra K; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 2007 Apr; 29(3):211-6. PubMed ID: 17520104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of haloperidol-induced orofacial dyskinesia by Murraya koenigii leaves in experimental animals.
    Patil R; Hiray Y; Shinde S; Langade P
    Pharm Biol; 2012 Jun; 50(6):691-7. PubMed ID: 22136413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulatory effect of neurosteroids in haloperidol-induced vacuous chewing movements and related behaviors.
    Bishnoi M; Chopra K; Kulkarni SK
    Psychopharmacology (Berl); 2008 Feb; 196(2):243-54. PubMed ID: 17955214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
    Haleem DJ; Samad N; Haleem MA
    Pharmacol Biochem Behav; 2007 May; 87(1):115-21. PubMed ID: 17498786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia.
    Singh A; Naidu PS; Kulkarni SK
    Eur J Pharmacol; 2003 Sep; 477(2):87-94. PubMed ID: 14519411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Co-administration of nitric oxide (NO) donors prevents haloperidol-induced orofacial dyskinesia, oxidative damage and change in striatal dopamine levels.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2009 Jan; 91(3):423-9. PubMed ID: 18789960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
    Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
    Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of reserpine-induced orofacial dyskinesia and cognitive dysfunction by quercetin.
    Naidu PS; Singh A; Kulkarni SK
    Pharmacology; 2004 Feb; 70(2):59-67. PubMed ID: 14685008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Valeriana officinalis does not alter the orofacial dyskinesia induced by haloperidol in rats: role of dopamine transporter.
    Fachinetto R; Villarinho JG; Wagner C; Pereira RP; Avila DS; Burger ME; Calixto JB; Rocha JB; Ferreira J
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Oct; 31(7):1478-86. PubMed ID: 17669571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.